Improving outcomes and combating AMR by giving the best drug every time

iFAST is addressing the $4bn (& growing) Antimicrobial Susceptibility Testing (AST) market.
We have a test that is up to 10x faster and cheaper than the gold standard, delivering results in 4 hours for urine samples and 8 hours for sepsis, saving lives and reducing the spread of antimicrobial resistance.

iFAST selected for the Healthcare Innovation Consortium's AMR Innovation Programme

We are delighted to have been selected to join five other companies looking to address antimicrobial resistance and will receive support to commercialise and scale our work.

The Problem

Bacteria are increasingly resistant to antibiotics – resistance levels are 20% - 98% and unpredictable. Current Antimicrobial Susceptibility Testing (AST) takes 48 -72 hours – patients deteriorate whilst waiting for the correct drug.

Prescribing inappropriate antibiotics leads to the spread of resistant infections, sepsis and death
Antimicrobial resistance (AMR) caused over 1 million deaths in 2019 – more than malaria or AIDS

iFAST reduces AST test time from 48+ to 4 hours

Blood/urine sample Incubated

Sample incubated for
a few hours then exposed to
range of antibiotics

Test itself takes
30 seconds

After a further 1 hour incubation, reader scans 5,000 individual bacteria

RESISTANT/
SUSCEPTIBLE Output

iFAST reader determines
optimum antibiotic for clinician to prescribe

The Benefits of iFAST

Speed

Results in only 4 hours (urine)
– 8 hours (blood) from raw sample

High throughput

Each reader performs
> 100 tests/day

Cost

Cheaper than current
gold standard methods

Small lab footprint

Reader is only 600x600mm
and fits neatly on a lab bench

Each sample analysed in less than a minute

The electrical properties of single bacteria are measured at high speed in a microfluidic chip.

Experienced and committed team

Dr Toby King

CEO

Lorem ipsum dolor sit amet, consec tetur adipiscing elit.
Prof Hywel Morgan

CTO

Lorem ipsum dolor sit amet, consec tetur adipiscing elit.
Dr Dan Spencer

VP Engineering

Lorem ipsum dolor sit amet, consec tetur adipiscing elit.
Prof Mark Sutton

Advisory Board Chair

Lorem ipsum dolor sit amet, consec tetur adipiscing elit.

Research Systems available NOW, with clinical systems expected to launch next year.

To find out more

If you would like find out more please send us
an email and we will get in touch.

Find our presentation, nature paper below & synopsis for hospitals below.

Latest News

Bacteria zapped in a fight with antibiotic resistance.

New spinout from University of Southampton is seeking to help solve one of the biggest threats to world health: antibiotic resistance

Spectacular results
with our first two hospital evaluations!

We are thrilled with the outcome of our first two hospital evaluations with our iFAST demonstrator platform - the results are spectacular! Both trials were comparing the iFAST technology with the hospital current standard of care (disk diffusion), using patient blood samples.

Latest Videos

Play Video

Watch iFAST video - 3.5 mins

Play Video

Watch iFAST video - 49 secs

Upcoming Events

On 16-17 November 2023 the sixth edition of ‘Emerging Antimicrobials and Diagnostics in AMR’ will take place at the iconic ‘De Bazel’ in the city centre of Amsterdam! Emerging Antimicrobials and Diagnostics in AMR (EADA) is the place where key players in research, business and funding of Antimicrobial resistance (AMR), come together with the aim to stimulate the development of antimicrobials and diagnostics for the global fight against AMR.

16.05  – 16th November 

iFAST – High-throughput, cost-effective AST in 3 hours – Clinical data

Presented by Dr Toby King, CEO iFAST Diagnostics

All Upcoming Events

Get in Touch

+44 (0)7788 595176

toby@ifastdiagnostics.com

 

Based in the United Kingdom

Improving outcomes and combating AMR by giving the best drug every time

iFAST is addressing the $4bn (& growing) Antimicrobial Susceptibility Testing (AST) market.
We have a test that is up to 10x faster and cheaper than the gold standard, delivering results in 4 hours for urine samples and 8 hours for sepsis, saving lives and reducing the spread of antimicrobial resistance.